Clinical characteristics of patients recruited in the study
| Characteristic . | Discovery and training phase . | P . | Validation and blinded testing phase . | P . | ||
|---|---|---|---|---|---|---|
| non-GVHD (n = 22) . | aGVHD (n = 63) . | non-GVHD (n = 41) . | aGVHD (n = 70) . | |||
| Median age (range) | 48.5 (24-72) | 50.5 (19-71) | 49 (19-72) | 58 (19-72) | ||
| Disease (%) | .431 | .833 | ||||
| Malignant* | 19 (86.4%) | 58 (92.1%) | 37 (90.2%) | 64 (91.4%) | ||
| Other† | 3 (13.6%) | 5 (7.90%) | 4 (9.80%) | 6 (8.60%) | ||
| Disease status at HCT‡(%) | .344 | .588 | ||||
| Low/mediate risk | 12 (54.5%) | 27 (42.9%) | 25 (61.0%) | 39 (55.7%) | ||
| High risk | 10 (45.5%) | 36 (57.1%) | 16 (39.0%) | 31 (44.3%) | ||
| Donor type (%) | .281 | .246 | ||||
| Related | 12 (54.5%) | 26 (41.3%) | 24 (58.5%) | 33 (47.1%) | ||
| Unrelated | 10 (45.5%) | 37 (58.7%) | 17 (41.5%) | 37 (52.9%) | ||
| Regimen type (%) | .149 | .014 | ||||
| Nonmyeloablative | 13 (59.1%) | 26 (41.3%) | 13 (31.7%) | 39 (55.7%) | ||
| Myeloablative | 9 (40.9%) | 37 (58.7%) | 28 (68.3%) | 31 (44.3%) | ||
| Maximum GVHD grade (%) | ||||||
| 1-2 | 42 (66.7%) | 46 (65.7%) | ||||
| ≥3 | 21 (33.3%) | 24 (34.3%) | ||||
| Organ target at GVHD onset (%) | ||||||
| Skin | 23 (36.5%) | 16 (22.9%) | ||||
| Gut | 3 (4.76%) | 13 (18.6%) | ||||
| Liver | 2 (3.17%) | 2 (2.86%) | ||||
| Multiple organs | 35 (55.6%) | 39 (55.7%) | ||||
| GVHD diagnosis day after HCT | ||||||
| Before day 14 | 3 (4.80%) | 4 (5.70%) | ||||
| Between days 14 and 42 | 33 (52.4%) | 21 (30.0%) | ||||
| After day 42 | 27 (42.8%) | 45 (64.3%) | ||||
| Characteristic . | Discovery and training phase . | P . | Validation and blinded testing phase . | P . | ||
|---|---|---|---|---|---|---|
| non-GVHD (n = 22) . | aGVHD (n = 63) . | non-GVHD (n = 41) . | aGVHD (n = 70) . | |||
| Median age (range) | 48.5 (24-72) | 50.5 (19-71) | 49 (19-72) | 58 (19-72) | ||
| Disease (%) | .431 | .833 | ||||
| Malignant* | 19 (86.4%) | 58 (92.1%) | 37 (90.2%) | 64 (91.4%) | ||
| Other† | 3 (13.6%) | 5 (7.90%) | 4 (9.80%) | 6 (8.60%) | ||
| Disease status at HCT‡(%) | .344 | .588 | ||||
| Low/mediate risk | 12 (54.5%) | 27 (42.9%) | 25 (61.0%) | 39 (55.7%) | ||
| High risk | 10 (45.5%) | 36 (57.1%) | 16 (39.0%) | 31 (44.3%) | ||
| Donor type (%) | .281 | .246 | ||||
| Related | 12 (54.5%) | 26 (41.3%) | 24 (58.5%) | 33 (47.1%) | ||
| Unrelated | 10 (45.5%) | 37 (58.7%) | 17 (41.5%) | 37 (52.9%) | ||
| Regimen type (%) | .149 | .014 | ||||
| Nonmyeloablative | 13 (59.1%) | 26 (41.3%) | 13 (31.7%) | 39 (55.7%) | ||
| Myeloablative | 9 (40.9%) | 37 (58.7%) | 28 (68.3%) | 31 (44.3%) | ||
| Maximum GVHD grade (%) | ||||||
| 1-2 | 42 (66.7%) | 46 (65.7%) | ||||
| ≥3 | 21 (33.3%) | 24 (34.3%) | ||||
| Organ target at GVHD onset (%) | ||||||
| Skin | 23 (36.5%) | 16 (22.9%) | ||||
| Gut | 3 (4.76%) | 13 (18.6%) | ||||
| Liver | 2 (3.17%) | 2 (2.86%) | ||||
| Multiple organs | 35 (55.6%) | 39 (55.7%) | ||||
| GVHD diagnosis day after HCT | ||||||
| Before day 14 | 3 (4.80%) | 4 (5.70%) | ||||
| Between days 14 and 42 | 33 (52.4%) | 21 (30.0%) | ||||
| After day 42 | 27 (42.8%) | 45 (64.3%) | ||||
P values were calculated using a 2-sided χ2 test.
Malignant disease included acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin disease, myelodysplastic syndrome, diffuse large B-Cell lymphoma, and multiple myeloma.
Other disease, which means nonmalignant disease, included severe aplastic anemia, sickle cell anemia, dyskeratosis congenita, myeloproliferative disorder, and myelofibrosis.
Low and high risk of disease status at BMT is according to CIBMTR guidelines.